- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02422524
Pretomanid in Adults With Hepatic Impairment
A Phase I, Single Dose, Open-Label Study Comparing the Pharmacokinetics and Safety of Pretomanid in Subjects With Mild, Moderate, and Severe Hepatic Impairment to Matched, Non-Hepatically Impaired Subjects
Study Overview
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Contact
- Name: Julius Wilder
- Phone Number: 19196848111
- Email: julius.wilder@dm.duke.edu
Study Locations
-
-
Missouri
-
Saint Louis, Missouri, United States, 63104-1015
- Saint Louis University Center for Vaccine Development
-
-
North Carolina
-
Durham, North Carolina, United States, 27710-4000
- Duke University School of Medicine - Duke Clinical Research Institute - Duke Clinical Research Unit
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
Inclusion Criteria for Patients with Hepatic Impairment (Groups 1-3):
- Subject is able to give voluntary written informed consent before any study related procedure is performed.
- 18-70 years of age, inclusive.
Acceptable laboratory values* obtained at screening (within 21 days prior to admission to the confinement/hospital unit) and either at or within 72 hours of admission to the confinement/hospital unit.
*Chemistry, complete blood count, AST, ALT, total bilirubin, alkaline phosphatase, albumin, and urinalysis deemed not clinically significant by the investigator.
Hepatic impairment classified as Child-Pugh class A (mild), B (moderate), or C (severe) criteria at screening for Groups 1, 2, or 3, respectively, and documented evidence of hepatic cirrhosis*.
*by biopsy, nuclear scan, CT, MRI, ultrasound, or other clinically acceptable methods
If female, not of childbearing potential* or agrees to avoid becoming pregnant by using acceptable contraception** during the duration of the study.
*Non-childbearing potential is defined as being post-menopausal for at least 2 years, status after bilateral oophorectomy or status after hysterectomy.
- Females of childbearing potential must agree to use two acceptable methods of contraceptives: bilateral tubal ligation; barrier method (condom) by the male partner (even if vasectomized); hormonal contraceptives; intrauterine contraceptive devices; diaphragm in combination with contraceptive jelly, cream, foam, or spermicide; and abstinence from sexual intercourse with men.
If subject is male and capable of reproduction, agrees to avoid fathering a child for three months after dosing by using an acceptable method of birth control*.
*In addition to the use of a barrier method (condom) even if vasectomized, acceptable methods of birth control are restricted to a monogamous relationship with a woman who agrees to use acceptable contraception as outlined in inclusion criterion #5, and abstinence from sexual intercourse with women.
- If the subject is female, a negative serum pregnancy test at screening and a negative urine pregnancy test at admission to the confinement/hospital unit.
- Willingness to comply with all protocol requirements.
Inclusion Criteria for Non-Hepatically Impaired Controls (Group 4):
- Subject is able to give voluntary written informed consent before any study related procedure is performed.
- 18-70 years of age, inclusive.
- Subject is a healthy volunteer as determined by no clinically significant findings from medical history, physical examination, vital signs, and 12-lead ECG as determined by the Site Investigator.
Acceptable laboratory values* obtained at screening (within 21 days prior to admission to the confinement/hospital unit) and either at or within 72 hours of admission to the confinement/hospital unit.
*Chemistry, complete blood count, AST, ALT, total bilirubin, alkaline phosphatase, albumin, and urinalysis within the reference range for the test laboratory, unless deemed not clinically significant by the investigator.
If female, not of childbearing potential* or agrees to avoid becoming pregnant by using acceptable contraception** during the duration of the study.
*Non-childbearing potential is defined as being post-menopausal for at least 2 years, status after bilateral oophorectomy or status after hysterectomy.
**Females of childbearing potential must agree to use two acceptable methods of contraceptives: bilateral tubal ligation; barrier method (condom) by the male partner (even if vasectomized); hormonal contraceptives; intrauterine contraceptive devices; diaphragm in combination with contraceptive jelly, cream, foam, or spermicide; and abstinence from sexual intercourse with men.
If subject is male and capable of reproduction, agrees to avoid fathering a child for three months after dosing by using an acceptable method of birth control*.
*In addition to the use of a barrier method (condom) even if vasectomized, acceptable methods of birth control are restricted to a monogamous relationship with a woman who agrees to use acceptable contraception as outlined in inclusion criterion #5, and abstinence from sexual intercourse with women.
- If the subject is female, a negative serum pregnancy test at screening and a negative urine pregnancy test at admission to the confinement/hospital unit.
- Willingness to comply with all protocol requirements.
Exclusion Criteria:
Exclusion Criteria for Patients with Hepatic Impairment (Groups 1-3):
- Hypokalemia (< 3.5mEq/L), severe hypomagnesemia (< 1.1 mg/dL) or severe hypocalcemia (< 7.5 mg/dL).
- AST or ALT > 10 times the upper limit of normal.
- Creatinine clearance < 60 ml/min.
- Inability to swallow tablets.
Presence of any condition or finding* which would jeopardize subject safety, impact study result validity, or diminish the subject's ability to undergo all study procedures and assessments**.
*in the opinion of the site investigator
**e.g., inability to draw PK samples
- History of fever or documented fever (oral temperature > / = 100.4 degrees F or > / = 38.0 degrees C) in the 48 hours prior to admission to the the confinement/hospital unit.
- Currently breastfeeding.
- History of chronic tobacco/nicotine use (> 10 cigarettes per day for 3 months minimum prior to admission).
- History of clinically significant allergy or severe side effects with nitroimidazoles (e.g., Metronidazole and related substances and azole antifungals or aromatase inhibitors).
- Receipt of an investigational drug, vaccine or biologic in a clinical trial within 30 days prior to screening.
Use of any over the counter (OTC) medication* within 7 days prior to admission to the confinement/hospital unit, unless** the substance would not likely impact the validity of the study results.
*including vitamins and herbal supplements, cough and cold medications.
**in the opinion of the site investigator
Treatment with CYP450 enzyme altering drugs* within 7 days prior to admission to the confinement/hospital unit, unless** the substance would not likely impact the validity of the study results.
except hormonal contraceptives
- in the opinion of the site investigator NOTE: See list of CYP450 enzyme altering drugs under the concomitant medications section.
- A positive blood screen for HIV.
A positive alcohol breath test (or other suitable test for alcohol) or a urine screen test for drugs of abuse* at screening and at admission to the confinement/hospital unit.
*Amphetamines, barbiturates, cocaine metabolites, marijuana, opiates, phencyclidine (PCP).
NOTE: Results of the urine screen test can be ignored if in the opinion of the PI the results can be explained by the concomitant medications history.
- Unwillingness to abstain from engaging in strenuous physical activity (e.g. running, bicycling, weightlifting, competitive sports) during the course of the study.
- Consumption of grapefruit juice in the 48 hours before admission to the confinement/hospital unit, or the inability to abstain from these until completion of Day 12.
- A QTcF interval > 450 msec (males) or > 450 msec (females) at screening (Visit 00A) or admission to the confinement/hospital unit (Visit 00B) or a history of prolonged QTc interval.
A family history* of Long QT Syndrome, premature cardiac death**, or sudden death without a preceding diagnosis of a condition*** that could be causative of sudden death.
*parents
**due to ischemic heart disease or sudden cardiac death before 55 years of age (men) or 65 years of age (women)
***such as known coronary artery disease, congestive heart failure, or terminal cancer
- Any clinically significant ECG abnormality, in the opinion of the site investigator, at screening and at admission to the confinement/hospital unit.
- Donation of > 500 mL blood within the 30 days prior to admission to the confinement/hospital unit.
- Plans to donate blood during the study or up to 14 days after dosing.
- Persons with a transjugular intrahepatic portosystemic shunt.
Exclusion Criteria for Non-Hepatically Impaired Controls (Group 4):
- Inability to swallow tablets.
Presence of any condition or finding* which would jeopardize subject safety, impact study result validity, or diminish the subject's ability to undergo all study procedures and assessments**.
*in the opinion of the site investigator
**e.g., inability to collect PK samples
- History of fever or documented fever (oral temperature > / = 100.4 degrees F or > / = 38.0 degrees C) in the 48 hours prior to admission to the confinement/hospital unit.
- Currently breastfeeding.
- History of chronic tobacco/nicotine use (> 10 cigarettes per day for 3 months minimum prior to admission to the confinement/hospital unit).
- History of seizures (other than febrile seizures during childhood) or known or suspected CNS disorders that may predispose to seizures.
- History of clinically significant allergy or severe side effects with nitroimidazoles (e.g., Metronidazole and related substances and azole antifungals or aromatase inhibitors).
- Receipt of an investigational drug, vaccine or biologic in a clinical trial within 30 days prior to screening.
Use of any over the counter (OTC) medication* within 7 days prior to admission to the confinement/hospital unit, unless** the substance would not likely impact the validity of the study results.
*including vitamins and herbal supplements, antacids, cough and cold medications.
**in the opinion of the site investigator
Use of prescription medication except hormonal contraceptives within 30 days prior to admission to the confinement/hospital unit, unless* the substance would not likely impact study result validity.
*in the opinion of the site investigator
Treatment with CYP450 enzyme altering drugs* within 7 days prior to admission to the confinement/hospital unit, unless** the substance would not likely impact the validity of the study results.
*except hormonal contraceptives
**in the opinion of the site investigator NOTE: See list of CYP450 enzyme altering drugs under the concomitant medications section.
- A positive blood screen for HIV.
- A positive blood screen for hepatitis B surface antigen (HBsAg), or hepatitis C antibody.
A positive alcohol breath test (or other suitable test for alcohol) or a urine screen test for drugs of abuse* at screening and at admission to the confinement/hospital unit.
*Amphetamines, barbiturates, benzodiazepines, cocaine metabolites, marijuana, opiates, phencyclidine (PCP).
- A history of alcohol abuse or dependence within the past 1 month prior to admission to the confinement/hospital unit.
- Unwillingness to abstain from engaging in strenuous physical activity (e.g. running, bicycling, weightlifting, competitive sports) during the course of the study.
- Consumption of grapefruit juice in the 48 hours before admission to the confinement/hospital unit, or the inability to abstain from these until completion of Day 12.
- A QTcF interval > 450 msec (males) or > 450 msec (females) at screening (Visit 00A) or admission to the confinement/hospital unit (Visit 00B) or a history of prolonged QTc interval.
A family history* of Long QT Syndrome, premature cardiac death**, or sudden death without a preceding diagnosis of a condition*** that could be causative of sudden death.
*parents
**due to ischemic heart disease or sudden cardiac death before 55 years of age (men) or 65 years of age (women)
***such as known coronary artery disease, congestive heart failure, or terminal cancer
- Any clinically significant ECG abnormality, in the opinion of the site investigator, at screening and at admission to the confinement/hospital unit.
- Donation of > 500 mL of blood within the 30 days prior to admission to the confinement/hospital unit.
- Plans to donate blood during the study or up to 14 days after dosing.
- Persons with a transjugular intrahepatic portosystemic shunt.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Child-Pugh A (Mild hepatic impairment)
6 Subjects will receive a single oral dose of 200mg Pretomanid tablets on day 1
|
Pretomanid (PA-824) is a nitroimidazooxazine.
All subjects will receive a single oral dose of 200 mg Pretomanid on day 1.
|
Experimental: Child-Pugh B (Moderate hepatic impairment)
6 Subjects will receive a single oral dose of 200mg Pretomanid tablets on day 1
|
Pretomanid (PA-824) is a nitroimidazooxazine.
All subjects will receive a single oral dose of 200 mg Pretomanid on day 1.
|
Experimental: Child-Pugh C (Severe hepatic impairment)
6 Subjects will receive a single oral dose of 200mg Pretomanid tablets on day 1
|
Pretomanid (PA-824) is a nitroimidazooxazine.
All subjects will receive a single oral dose of 200 mg Pretomanid on day 1.
|
Experimental: Non-hepatically impaired controls
18 matched Subjects will receive a single oral dose of 200mg Pretomanid tablets on day 1
|
Pretomanid (PA-824) is a nitroimidazooxazine.
All subjects will receive a single oral dose of 200 mg Pretomanid on day 1.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
AUC(0-infinity): Area under the concentration time-curve extrapolated to infinity at specified pre-dose and post-dose time points
Time Frame: Day 1 to Day 5
|
Day 1 to Day 5
|
AUC(0-last): Area under the concentration time-curve to the last concentration above the lower limit of quantitation at specified pre-dose and post-dose time points
Time Frame: Day 1 to Day 5
|
Day 1 to Day 5
|
CL/F: Apparent oral clearance calculated from Dose/AUC(0-infinifty) at specified pre-dose and post-dose time points
Time Frame: Day 1 to Day 5
|
Day 1 to Day 5
|
Cmax: Maximum Pretomanid concentration at specified pre-dose and post-dose time points
Time Frame: Day 1 to Day 5
|
Day 1 to Day 5
|
t(1/2): Apparent terminal elimination half-life at specified pre-dose and post-dose time points
Time Frame: Day 1 to Day 5
|
Day 1 to Day 5
|
Tmax: Time of maximum Pretomanid concentration at specified pre-dose and post-dose time points
Time Frame: Day 1 to Day 5
|
Day 1 to Day 5
|
Vd/F: Apparent Volume of Distribution at specified pre-dose and post-dose time points
Time Frame: Day 1 to Day 5
|
Day 1 to Day 5
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Incidence of related adverse events
Time Frame: Day 1 to Day 12
|
Day 1 to Day 12
|
Incidence of serious adverse events
Time Frame: Day 1 to Day 12
|
Day 1 to Day 12
|
Severity of related adverse events
Time Frame: Day 1 to Day 12
|
Day 1 to Day 12
|
Severity of serious adverse events
Time Frame: Day 1 to Day 12
|
Day 1 to Day 12
|
Summary of ECG data
Time Frame: Day -1 and Day 12
|
Day -1 and Day 12
|
Summary of physical examination findings (height at baseline, and weight at serial time points)
Time Frame: Day -1 to Day 12
|
Day -1 to Day 12
|
Summary of safety laboratory parameters
Time Frame: Day -1, 2, 5, and 12
|
Day -1, 2, 5, and 12
|
Summary of vital signs at serial time points
Time Frame: Day -1 to Day 12
|
Day -1 to Day 12
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimated)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 13-0053
- HHSN272201300017I
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Tuberculosis
-
Global Alliance for TB Drug DevelopmentCompletedTuberculosis | Tuberculosis, Pulmonary | Pulmonary Disease | Multi Drug Resistant Tuberculosis | Drug Sensitive Tuberculosis | Drug-resistant Tuberculosis | Mycobacterium Tuberculosis InfectionUnited States
-
Global Alliance for TB Drug DevelopmentCompletedTuberculosis | Tuberculosis, Pulmonary | Pulmonary Disease | Multi Drug Resistant Tuberculosis | Drug Sensitive Tuberculosis | Drug-resistant Tuberculosis | Mycobacterium Tuberculosis InfectionUnited States
-
University of Cape TownUniversity of Stellenbosch; University of Cape Town Lung Institute; University... and other collaboratorsCompletedTuberculosis | Multidrug Resistant Tuberculosis | Extensively-drug Resistant TuberculosisSouth Africa
-
Universiteit AntwerpenAurum Institute; University of Stellenbosch; University of the Free State; Free...RecruitingDrug-resistant Tuberculosis | Rifampicin Resistant Tuberculosis | Pulmonary Tuberculoses | Multidrug Resistant TuberculosisSouth Africa
-
Assistance Publique - Hôpitaux de ParisCompletedExtrapulmonary Tuberculosis | Lymph Node Tuberculosis | Bone TuberculosisFrance
-
Centers for Disease Control and PreventionBoston University; Pfizer; Columbia University; University of Texas; University of... and other collaboratorsCompletedMulti-Drug Resistant Tuberculosis | Extensively Drug Resistant TuberculosisSouth Africa
-
University Medical Center GroningenCompletedMultidrug-resistant Tuberculosis | Extensively Drug-resistant TuberculosisNetherlands
-
Foundation for Innovative New Diagnostics, SwitzerlandInstitute of Tropical Medicine, Belgium; Research Center Borstel; National Institute...CompletedMultidrug-Resistant Tuberculosis | Isoniazid Resistant Pulmonary Tuberculosis | Rifampicin Resistant Tuberculosis | Pulmonary Tuberculoses
-
National Institute of Allergy and Infectious Diseases...CompletedPulmonary Tuberculosis | Multidrug Resistant Tuberculosis | Extensively Drug Resistant TuberculosisKorea, Republic of
-
Wits Health Consortium (Pty) LtdUniversity of Cape Town; Perinatal HIV Research Unit of the University of the... and other collaboratorsActive, not recruitingTuberculosis | Multi Drug Resistant Tuberculosis | Rifampicin Resistant Tuberculosis | Extensively Drug-Resistant Tuberculosis | Pre-XDR-TBSouth Africa
Clinical Trials on PA-824
-
Global Alliance for TB Drug DevelopmentCompleted
-
National Institute of Allergy and Infectious Diseases...Not yet recruitingRenal Impairment | TuberculosisUnited States
-
Global Alliance for TB Drug DevelopmentCompletedMulti-drug Resistant TuberculosisUnited States
-
Global Alliance for TB Drug DevelopmentCompleted
-
Global Alliance for TB Drug DevelopmentCompletedPulmonary TuberculosisSouth Africa
-
Global Alliance for TB Drug DevelopmentCompletedFood Effect Study on the Bioavailability and PK of PA-824 Tablets in Healthy Adult Subjects (CL-003)TuberculosisUnited States
-
Global Alliance for TB Drug DevelopmentCompletedPulmonary Tuberculosis
-
BayerCompletedHemophilia ABelgium, New Zealand, Netherlands, Greece, United Kingdom, Austria, United States, Italy, Romania, Bulgaria, Canada, Israel, Poland, Lithuania, Norway, Argentina, Spain
-
Global Alliance for TB Drug DevelopmentCompletedPulmonary TuberculosisSouth Africa
-
Global Alliance for TB Drug DevelopmentCompleted